BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 125 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.63 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $20,909,881 | +0.7% | 2,953,373 | +0.1% | 0.00% | 0.0% |
Q2 2023 | $20,766,578 | -60.7% | 2,949,798 | -53.4% | 0.00% | 0.0% |
Q1 2023 | $52,834,066 | -35.4% | 6,335,020 | -11.0% | 0.00% | -75.0% |
Q4 2022 | $81,749,023 | +13.7% | 7,120,995 | +24.8% | 0.01% | +14.3% |
Q3 2022 | $71,910,000 | +31.0% | 5,707,067 | +10.0% | 0.01% | +40.0% |
Q2 2022 | $54,887,000 | -59.9% | 5,187,777 | -38.3% | 0.01% | -54.5% |
Q1 2022 | $136,819,000 | +153.5% | 8,414,458 | +116.0% | 0.01% | +175.0% |
Q4 2021 | $53,963,000 | +234.1% | 3,896,248 | +246.6% | 0.00% | +300.0% |
Q3 2021 | $16,154,000 | -9.1% | 1,124,179 | -0.0% | 0.00% | 0.0% |
Q2 2021 | $17,776,000 | +116.8% | 1,124,333 | +39.4% | 0.00% | 0.0% |
Q1 2021 | $8,201,000 | +36.5% | 806,386 | +0.0% | 0.00% | 0.0% |
Q4 2020 | $6,007,000 | +25.1% | 806,284 | -42.3% | 0.00% | – |
Q3 2020 | $4,802,000 | -60.6% | 1,398,084 | -45.3% | 0.00% | -100.0% |
Q2 2020 | $12,182,000 | +138.3% | 2,556,584 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $5,113,000 | +15.2% | 2,556,584 | +98.7% | 0.00% | – |
Q4 2019 | $4,439,000 | -13.4% | 1,286,541 | -28.1% | 0.00% | -100.0% |
Q3 2019 | $5,124,000 | -53.3% | 1,788,541 | -38.2% | 0.00% | 0.0% |
Q2 2019 | $10,971,000 | -61.1% | 2,894,741 | -16.5% | 0.00% | -66.7% |
Q1 2019 | $28,229,000 | +16.9% | 3,467,998 | +15.9% | 0.00% | 0.0% |
Q4 2018 | $24,146,000 | -15.7% | 2,992,009 | -20.3% | 0.00% | 0.0% |
Q3 2018 | $28,641,000 | +13.1% | 3,753,803 | -15.0% | 0.00% | 0.0% |
Q2 2018 | $25,319,000 | +20.1% | 4,418,631 | 0.0% | 0.00% | 0.0% |
Q1 2018 | $21,077,000 | +37.4% | 4,418,631 | +41.4% | 0.00% | +50.0% |
Q4 2017 | $15,342,000 | -6.3% | 3,124,676 | 0.0% | 0.00% | 0.0% |
Q3 2017 | $16,373,000 | -5.8% | 3,124,676 | 0.0% | 0.00% | 0.0% |
Q2 2017 | $17,373,000 | +42.0% | 3,124,676 | +114.5% | 0.00% | 0.0% |
Q1 2017 | $12,238,000 | +162.1% | 1,456,885 | +97.5% | 0.00% | +100.0% |
Q4 2016 | $4,670,000 | +342.2% | 737,723 | +207.9% | 0.00% | – |
Q3 2016 | $1,056,000 | +105.4% | 239,562 | +32.3% | 0.00% | – |
Q2 2016 | $514,000 | -81.8% | 181,100 | -81.9% | 0.00% | – |
Q1 2016 | $2,830,000 | -96.3% | 1,000,000 | -86.6% | 0.00% | -100.0% |
Q4 2015 | $77,277,000 | -12.5% | 7,488,027 | -3.4% | 0.01% | -23.1% |
Q3 2015 | $88,351,000 | -38.6% | 7,750,127 | -19.6% | 0.01% | -27.8% |
Q2 2015 | $143,999,000 | +47.0% | 9,644,931 | -11.1% | 0.02% | +50.0% |
Q1 2015 | $97,958,000 | -22.7% | 10,848,020 | +4.1% | 0.01% | -25.0% |
Q4 2014 | $126,761,000 | +21.7% | 10,424,425 | -2.1% | 0.02% | +14.3% |
Q3 2014 | $104,121,000 | -23.9% | 10,646,325 | -0.8% | 0.01% | -22.2% |
Q2 2014 | $136,887,000 | +43.9% | 10,736,225 | +19.4% | 0.02% | +38.5% |
Q1 2014 | $95,139,000 | +380.8% | 8,992,381 | +245.4% | 0.01% | +333.3% |
Q4 2013 | $19,788,000 | +9794.0% | 2,603,700 | +9368.0% | 0.00% | – |
Q3 2013 | $200,000 | – | 27,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |